erlotinib hydrochloride has been researched along with Cranial Nerve II Injuries in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, G | 1 |
| Atwal, J; Chen, DF; Cho, KS; Gore, B; He, Z; Kim, JA; Koprivica, V; Lin, E; Park, JB; Tessier-Lavigne, M; Yiu, G | 1 |
2 other study(ies) available for erlotinib hydrochloride and Cranial Nerve II Injuries
| Article | Year |
|---|---|
Neuroscience. Cancer drugs may help injured nerve cells regrow their axons.
Topics: Animals; Antineoplastic Agents; Axons; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Mice; Nerve Crush; Nerve Regeneration; Neurons; Optic Nerve Injuries; Quinazolines; Rats; Signal Transduction; Spinal Cord Injuries | 2005 |
EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans.
Topics: Animals; Axons; Calcium; Cells, Cultured; Chondroitin Sulfate Proteoglycans; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; GPI-Linked Proteins; Humans; Mice; Myelin Proteins; Nerve Crush; Nerve Regeneration; Neurites; Nogo Proteins; Nogo Receptor 1; Optic Nerve; Optic Nerve Injuries; Phosphorylation; Quinazolines; Receptors, Cell Surface; Retinal Ganglion Cells; Signal Transduction; Tyrphostins | 2005 |